JP2009504780A5 - - Google Patents

Download PDF

Info

Publication number
JP2009504780A5
JP2009504780A5 JP2008527189A JP2008527189A JP2009504780A5 JP 2009504780 A5 JP2009504780 A5 JP 2009504780A5 JP 2008527189 A JP2008527189 A JP 2008527189A JP 2008527189 A JP2008527189 A JP 2008527189A JP 2009504780 A5 JP2009504780 A5 JP 2009504780A5
Authority
JP
Japan
Prior art keywords
aliphatic
carbonyl
aryl
alicyclic
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008527189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504780A (ja
JP5203203B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/032481 external-priority patent/WO2007022459A2/en
Publication of JP2009504780A publication Critical patent/JP2009504780A/ja
Publication of JP2009504780A5 publication Critical patent/JP2009504780A5/ja
Application granted granted Critical
Publication of JP5203203B2 publication Critical patent/JP5203203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008527189A 2005-08-19 2006-08-18 製造工程および中間体 Expired - Fee Related JP5203203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70996405P 2005-08-19 2005-08-19
US60/709,964 2005-08-19
US81004206P 2006-06-01 2006-06-01
US60/810,042 2006-06-01
PCT/US2006/032481 WO2007022459A2 (en) 2005-08-19 2006-08-18 Processes and intermediates

Publications (3)

Publication Number Publication Date
JP2009504780A JP2009504780A (ja) 2009-02-05
JP2009504780A5 true JP2009504780A5 (https=) 2009-10-01
JP5203203B2 JP5203203B2 (ja) 2013-06-05

Family

ID=37708299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527189A Expired - Fee Related JP5203203B2 (ja) 2005-08-19 2006-08-18 製造工程および中間体

Country Status (24)

Country Link
US (3) US7776887B2 (https=)
EP (4) EP2357170A1 (https=)
JP (1) JP5203203B2 (https=)
KR (4) KR20130038947A (https=)
CN (2) CN101291909B (https=)
AR (1) AR058025A1 (https=)
AT (1) ATE463480T1 (https=)
AU (1) AU2006279357B2 (https=)
BR (1) BRPI0615029A2 (https=)
CA (1) CA2619659A1 (https=)
CY (2) CY1110214T1 (https=)
DE (1) DE602006013492D1 (https=)
DK (2) DK1934179T3 (https=)
ES (2) ES2344156T3 (https=)
IL (2) IL189585A (https=)
NZ (3) NZ604087A (https=)
PL (3) PL1934179T4 (https=)
PT (2) PT2194043E (https=)
RU (2) RU2446171C2 (https=)
SG (1) SG2014013338A (https=)
SI (2) SI2194043T1 (https=)
TW (2) TWI391376B (https=)
WO (1) WO2007022459A2 (https=)
ZA (1) ZA200801791B (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1019A (en) * 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
UY28500A1 (es) * 2003-09-05 2005-04-29 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc.
AU2006275413B2 (en) * 2005-08-02 2012-07-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2007022459A2 (en) 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
JP5313124B2 (ja) * 2006-03-16 2013-10-09 バーテックス ファーマシューティカルズ インコーポレイテッド 立体的化合物を製造するための方法および中間体
CN101610999A (zh) * 2006-12-15 2009-12-23 先灵公司 α-酮酰胺的亚硫酸氢盐纯化方法
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
HRP20120330T1 (hr) * 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
NZ583699A (en) * 2007-08-30 2012-04-27 Vertex Pharma Co-crystals of vx-950 (telaprevir) other components and pharmaceutical compositions comprising the same
US8431733B2 (en) * 2008-03-12 2013-04-30 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
US8143448B2 (en) 2008-06-13 2012-03-27 Virobay, Inc. Process for the preparation of (3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamide derivatives
CN102816106A (zh) 2008-06-24 2012-12-12 默沙东公司 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法
WO2011103933A1 (en) * 2010-02-25 2011-09-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg PROCESS FOR THE PREPARATION OF α-ACYLOXY β-FORMAMIDO AMIDES
WO2011153423A2 (en) 2010-06-03 2011-12-08 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN102167680B (zh) * 2011-03-23 2014-07-02 合亚医药科技（上海）有限公司 八氢环戊基并[c]吡咯羧酸衍生物的制备方法
WO2012158513A1 (en) 2011-05-13 2012-11-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
WO2012158515A1 (en) * 2011-05-13 2012-11-22 Vertex Phamaceuticals Incorporated Process for the preparation of protease inhibitors
JP2013010738A (ja) * 2011-05-31 2013-01-17 Sumitomo Chemical Co Ltd エステル化合物の製造方法
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013072328A1 (en) 2011-11-14 2013-05-23 Sanofi Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
CN103183632A (zh) * 2011-12-29 2013-07-03 山东方明药业集团股份有限公司 一种3-氮杂双环辛烷盐酸盐的提纯方法
ITMI20120192A1 (it) * 2012-02-13 2013-08-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
ITMI20120359A1 (it) 2012-03-07 2013-09-08 Dipharma Francis Srl Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali
ITMI20121668A1 (it) * 2012-10-05 2014-04-06 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
ITMI20120391A1 (it) * 2012-03-13 2013-09-14 Dipharma Francis Srl Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali
WO2013136265A1 (en) 2012-03-13 2013-09-19 Dipharma Francis S.R.L. Synthesis of an intermediate of an antiviral compound
IN2014DN08260A (https=) 2012-03-16 2015-05-15 Sandoz Ag
ITMI20120608A1 (it) 2012-04-13 2013-10-14 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali in forma amorfa
ITMI20120800A1 (it) * 2012-05-10 2013-11-11 Dipharma Francis Srl Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali
AR091192A1 (es) 2012-05-30 2015-01-21 Chemo Iberica Sa Procedimiento multicomponente para la preparacion de compuestos biciclicos
CN103450066B (zh) * 2012-05-30 2017-03-15 博瑞生物医药（苏州）股份有限公司 特拉匹韦中间体的制备方法
ITMI20120990A1 (it) * 2012-06-07 2013-12-08 Dipharma Francis Srl Sintesi di un inibitore delle proteasi virali
CN104470914A (zh) * 2012-06-20 2015-03-25 桑多斯股份公司 替拉瑞韦和波普瑞韦或者其药学上可接受的盐或溶剂合物和中间产物包括经Mukaiyama羟醛加成制备的β-氨基酸的合成
WO2013189978A1 (en) 2012-06-20 2013-12-27 Sandoz Ag PROCESS FOR PREPARING ß-AMINO ACID DERIVATIVES AND USE OF SAID PROCESS FOR PREPARING TELAPREVIR
WO2014019179A1 (zh) * 2012-08-01 2014-02-06 上海迪赛诺药业有限公司 特拉匹韦及其中间体的制备方法
WO2014033667A1 (en) 2012-08-30 2014-03-06 Ranbaxy Laboratories Limited Process for the preparation of telaprevir
CN102875648B (zh) * 2012-09-26 2014-02-19 深圳翰宇药业股份有限公司 一种制备特拉匹韦的方法
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
ITMI20122036A1 (it) 2012-11-29 2014-05-30 Dipharma Francis Srl Sintesi di un intermedio di un composto antivirale
WO2014096343A1 (en) * 2012-12-21 2014-06-26 Sandoz Ag Novel forms of telaprevir
WO2014096374A1 (en) 2012-12-21 2014-06-26 Sandoz Ag Process for the synthesis of pyrrolidines and pyrroles
CN103936651B (zh) * 2013-01-18 2016-06-22 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅲ及其制备方法和应用
ITMI20130706A1 (it) * 2013-04-30 2014-10-31 Dipharma Francis Srl Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi
CN103288671B (zh) * 2013-06-20 2014-10-29 上海步越化工科技有限公司 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法
WO2014203208A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and intermediates thereof
WO2014203224A1 (en) 2013-06-21 2014-12-24 Ranbaxy Laboratories Limited Process for the preparation of telaprevir and its intermediates
CN104292146B (zh) * 2013-06-24 2017-04-26 上海医药工业研究院 特拉匹韦中间体及其制备方法
CN103342656B (zh) * 2013-07-04 2015-04-08 苏州永健生物医药有限公司 特拉匹韦中间体的合成方法
CN103435532B (zh) * 2013-09-02 2015-07-08 苏州永健生物医药有限公司 波普瑞韦中间体的合成方法
WO2015036522A1 (en) * 2013-09-13 2015-03-19 Sandoz Ag Process for the preparation and isolation of (s)-3-amino-n-cyclopropyl-2,2-dialkoxyhexanamide and (s)-tert-butyl(1-(cyclopropylamino)-2,2-dialkoxy-1-oxohexan-3-yl)carbamate and use thereof for the preparation of telaprevir
EP3060573B1 (en) 2013-10-23 2019-07-17 Kaneka Corporation Tetrapeptide compound and method for producing same
CN103664739B (zh) * 2013-12-10 2016-04-27 湖南科源生物制品有限公司 一种特拉匹韦中间体的制备方法
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN105646329A (zh) * 2014-11-28 2016-06-08 重庆圣华曦药业股份有限公司 一种制备特拉匹韦中间体的方法
CN105111129A (zh) * 2015-08-24 2015-12-02 上海合全药业股份有限公司 (1S,3aR,6aS)-八氢环戊烯并[C]吡咯-1-羧酸叔丁酯草酸盐的制备方法
CN105601556B (zh) * 2015-12-02 2018-11-13 镇江市高等专科学校 特拉匹韦双环吡咯烷中间体的制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
JP7584418B2 (ja) 2018-12-04 2024-11-15 ブリストル－マイヤーズ スクイブ カンパニー 多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
PH12022553378A1 (en) 2020-06-10 2024-03-25 Univ Leuven Kath Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
JP2024525589A (ja) 2021-07-09 2024-07-12 アリゴス セラピューティクス インコーポレイテッド 抗ウイルス化合物
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
US5468858A (en) * 1993-10-28 1995-11-21 The Board Of Regents Of Oklahoma State University Physical Sciences N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents
JPH0967344A (ja) * 1995-09-05 1997-03-11 Koei Chem Co Ltd 光学活性ｎ−ベンジルオキシカルボニルピペコリン酸の製造方法
EP0907659A1 (en) 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
JP3863230B2 (ja) 1996-08-16 2006-12-27 株式会社カネカ β−アミノ−α−ヒドロキシ酸誘導体の製造方法
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
IT1299134B1 (it) 1998-02-02 2000-02-29 Angeletti P Ist Richerche Bio Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
DE19836514A1 (de) 1998-08-12 2000-02-17 Univ Stuttgart Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette
GB9825946D0 (en) 1998-11-26 1999-01-20 Angeletti P Ist Richerche Bio Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
GB2363605B (en) 1999-03-12 2004-02-04 Ajinomoto Kk Process for the preparation of alpha-aminoketone derivatives
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US7122627B2 (en) 1999-07-26 2006-10-17 Bristol-Myers Squibb Company Lactam inhibitors of Hepatitis C virus NS3 protease
WO2001007407A1 (en) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Lactam inhibitors of hepatitis c virus ns3 protease
EP1261611A2 (en) 2000-02-29 2002-12-04 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
AU2001243515A1 (en) * 2000-03-08 2001-09-17 Rhode Island Hospital, A Lifespan Partner Combination drug therapy
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
ES2317900T3 (es) 2000-04-05 2009-05-01 Schering Corporation Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2.
AU2001253621A1 (en) 2000-04-19 2001-11-07 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
CN1498224A (zh) 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
SK742003A3 (en) 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6846806B2 (en) 2000-10-23 2005-01-25 Bristol-Myers Squibb Company Peptide inhibitors of Hepatitis C virus NS3 protein
ES2263687T3 (es) 2000-11-20 2006-12-16 Bristol-Myers Squibb Company Inhibidores tripeptidicos de la hepatitis c.
WO2002048157A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
WO2002048116A2 (en) 2000-12-13 2002-06-20 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
GB0107924D0 (en) 2001-03-29 2001-05-23 Angeletti P Ist Richerche Bio Inhibitor of hepatitis C virus NS3 protease
IL159087A0 (en) 2001-07-11 2004-05-12 Vertex Pharma Bridged bicyclic compounds and pharmaceutical compositions containing the same
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
CA2515216A1 (en) 2003-02-07 2004-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis c serine protease inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
WO2004092161A1 (en) 2003-04-11 2004-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JP4525982B2 (ja) * 2003-09-26 2010-08-18 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼの大環状インヒビター
DE602005015834D1 (de) * 2004-02-27 2009-09-17 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2007022459A2 (en) 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
ES2381410T3 (es) * 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC

Similar Documents

Publication Publication Date Title
JP2009504780A5 (https=)
BRPI0413232B8 (pt) composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto
CO5261605A1 (es) Compustos farmaceuticos
EA200602290A1 (ru) Лиганды crth2 рецептора и их применение
GB0206860D0 (en) Compounds
EP1600442A4 (en) HETEROARYLCARBAMOYLBENZOLDERIVATE
EA200401615A1 (ru) ИНГИБИТОРЫ АКТИВАЦИИ NF-kB
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
AR038259A1 (es) Derivados sustituidos de aril-1,4-pirazina, composiciones farmaceuticas que los contienen, su uso para la elaboracion de medicamentos, articulo de fabricacion que los comprende, metodo para inhibir la union del crf al receptor de crf1, metodo para clasificar ligandos de receptores del crf y metodo p
TW200500362A (en) 5-membered heteroaromatic ring compound and pharmaceutical use thereof
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
EP0282971A3 (en) Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
CA2464358A1 (en) Alkyl ether derivatives or their salts
WO2008093674A1 (ja) キナーゼ阻害活性を有する新規チアジアゾール誘導体
DE60317889D1 (de) Antivirale bicyclo-4.4.0-derivate
WO2009010789A3 (en) Pyrimidine derivatives 934
EP1020452A4 (en) benzimidazole derivatives
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
WO2004074247A3 (en) A1 adenosine receptor antagonists
MX9300552A (es) Derivados de etanolamina
WO2004014868A3 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
NO964045D0 (no) Sulfonamidderivater
DK1154688T3 (da) Forhindring af marin biologisk begroning af overflader
AR012092A1 (es) Compuestos derivados de aril y heteroaril carboxamida, procedimiento para su preparacion, composicion farmaceutica que lo comprenden, y el uso de dichosderivados para la fabricacion de un medicamento.